Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?

Auteurs : Morgan G, Aftimos P, Awada A
Jaar : 2016
Journal : Curr Opin Oncol
Volume : 28(5)
Pagina's : 441-6

Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist.

Auteurs : Deliens C, Deliens G, Filleul O, Pepersack T, Awada A, Piccart-Gebhart M, Praet JP, Dal Lago L
Jaar : 2016
Journal : J Geriatr Oncol
Volume : 7(6)
Pagina's : 463-70

Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.

Auteurs : Sideris S, Aoun F, Zanaty M, Martinez NC, Latifyan S, Awada A, Gil T
Jaar : 2016
Journal : Mol Clin Oncol
Volume : 4
Pagina's : 1063-1067

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.

Auteurs : Kourie HR, Chaix M, Gombos A, Aftimos P, Awada A
Jaar : 2016
Journal : Expert Opin Drug Metab Toxicol
Volume : 12(8)
Pagina's : 947-57

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

Auteurs : Awada A, Cortés J, Martín M, Aftimos P, Oliveira M, López-Tarruella S, Espie M, Lardelli P, Extremera S, Fernández-García EM, Delaloge S
Jaar : 2016
Journal : Clin Breast Cancer
Volume : 16(5)
Pagina's : 364-71

Rare side-effects of checkpoint inhibitors.

Auteurs : Kourie HR, Awada G, Awada A
Jaar : 2016
Journal : Curr Opin Oncol
Volume : 28
Pagina's : 295-305

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.

Auteurs : Agarwal N, Machiels JP, Suárez C, Lewis N, Higgins M, Wisinski K, Awada A, Maur M, Stein M, Hwang A, Mosher R, Wasserman E, Wu G, Zhang H, Zieba R, Elmeliegy M
Jaar : 2016
Journal : Oncologist
Volume : 21(5)
Pagina's : 535-6

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

Auteurs : Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A
Jaar : 2016
Journal : Eur J Cancer
Volume : 60
Pagina's : 117-124

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Auteurs : Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA
Jaar : 2016
Journal : JAMA Oncol
Volume : 2(12)
Pagina's : 1557-64

Learning from the tsunami" of immune checkpoint inhibitors in 2015."

Auteurs : Kourie HR, Awada G, Awada A
Jaar : 2016
Journal : Crit Rev Oncol Hematol
Volume : 101
Pagina's : 213-220

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.

Auteurs : Limentani SA, Campone M, Dorval T, Curigliano G, de Boer R, Vogel C, White S, Bachelot T, Canon JL, Disis M, Awada A, Berlière M, Amant F, Levine E, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF
Jaar : 2016
Journal : Breast Cancer Res Treat
Volume : 156(2)
Pagina's : 319-30

Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer.

Auteurs : Twelves C, Jove M, Gombos A, Awada A
Jaar : 2016
Journal : Crit Rev Oncol Hematol
Volume : 100
Pagina's : 74-87

Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice.

Auteurs : Lalami Y, Awada A
Jaar : 2016
Journal : Cancer Treat Rev
Volume : 43
Pagina's : 113-23

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.

Auteurs : Awada A, Campone M, Varga A, Aftimos P, Frenel JS, Bahleda R, Gombos A, Bourbouloux E, Soria JC
Jaar : 2016
Journal : Anticancer Drugs
Volume : 27(4)
Pagina's : 342-8

p53 Reactivation by PRIMA-1 Met (APR-246) sensitises V600E/K BRAF melanoma to vemurafenib.

Auteurs : Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Sales F, Van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G
Jaar : 2016
Journal : Eur J Cancer
Volume : 55
Pagina's : 98-110

Emerging Drugs Targeting Human Epidermal Growth Factor Receptor 2 (Her2) In The Treatment Of Breast Cancer.

Auteurs : Awada G, Gombos A, Aftimos P, Awada A
Jaar : 2016
Journal : Expert Opin Emerg Drugs
Volume : 21(1)
Pagina's : 91-101

Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients.

Auteurs : Sideris S, Aoun F, Martinez Chanza N, Latifyan S, Awada A, Costante G, Gil T
Jaar : 2016
Journal : J Endocrinol Invest
Volume : 39(7)
Pagina's : 729-38

Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?

Auteurs : Kourie HR, Awada G, Awada A
Jaar : 2016
Journal : Future Oncol
Volume : 12(4)
Pagina's : 429-31

A Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early FDG PET-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.

Auteurs : Lalami Y, Garcia C, Flamen P, Ameye L, Paesmans M, Awada A
Jaar : 2016
Journal : Head Neck
Volume : 38(3)
Pagina's : 347-54

A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.

Auteurs : Schöffski P, Aftimos P, Dumez H, Deleporte A, De Block K, Costermans J, Billiet M, Meeus MA, Lee C, Schnell D, Goeldner RG, Awada A
Jaar : 2016
Journal : Cancer Chemother Pharmacol
Volume : 77(1)
Pagina's : 99-108